Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 4 2Phase 1 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Genitourinary 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Pancreatic Fistula 1Hypoglycemia 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Oxaliplatin 21Capecitabine 19Fluorouracil 16Bevacizumab 16Esomeprazole 11Sorafenib 10Irinotecan 9Leucovorin 8Radiofrequency Ablation 7Propofol 7Bismuth 7Morphine 6Gemcitabine 6Folfox protocol 6Amoxicillin 6lenvatinib 5gadolinium ethoxybenzyl DTPA 5Tetracycline 5Sevoflurane 5S 1 (combination) 5Drug Therapy 5Control Groups 5Cisplatin 5sodium glycididazole 4fish oil triglycerides 4ferric carboxymaltose 4Sodium Chloride 4Ropivacaine 4Ribavirin 4Hepatectomy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × pasireotide × Gastrointestinal × Clear all
NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

NCT02775227 2020-08-24

HYPAR

Helsinki University Central Hospital

Phase 4 Active not recruiting
126 enrolled
Gastrointestinal

Pancreatic Fistula, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡